Recognized as a “Rising Star” and “Next Generation Lawyer” in antitrust litigation, Abram Ellis is a Partner in the Firm’s Washington, D.C. office. His practice comprises all aspects of competition law, from defending clients against complex class action antitrust litigation to helping clients obtain regulatory clearance from domestic and international competition authorities for significant transactions. An integral member of the “Antitrust Team of the Year” (Chambers USA 2016), Abram is particularly experienced in antitrust litigation involving complex financial instruments, the healthcare industry and employment issues. In addition to his robust antitrust practice, Abram advises leading private equity funds, financial institutions and major corporations on regulatory and compliance matters relating to cross-border activities, including with respect to OFAC, FCPA and export matters. Recent representations include: representing Change Healthcare in the DOJ’s challenge of UnitedHealthGroup’s acquisition of Change Healthcare; RPM/Euclid in connection with claims that it fixed prices with respect to concrete additives and admixtures; Marinette Marine in a claim that it participated in a no-poach agreement with firms that employee naval engineers; Sun Communities in defense of claims that it fixed prices on manufactured home lots; the OWGR in ongoing litigation involving LIV; HCA in the FTC’s review of the sale of certain hospitals in Louisiana by HCA; HCA in pending antitrust litigation in North Carolina state and federal court alleging HCA engaged in monopolistic conduct in violation of state and federal antitrust laws; Covestro in antitrust class actions involving MDI and TDI; Tyson Foods in a wage fixing antitrust class action alleging a decades-long conspiracy to fix wages; a major pharmaceutical and medical supply company in dismissal of antitrust class action concerning alleged price-fixing conspiracy among manufacturers of generic pharmaceuticals; Micron in dismissal of a proposed antitrust class action alleging a conspiracy involving DRAM; HCA in the FTC’s challenge of HCA’s proposed acquisition of certain hospital assets from Steward Healthcare; and JPMorgan in antitrust and CEA class actions concerning the alleged manipulation of LIBOR; ISDA in antitrust class actions and government investigations concerning credit default swaps.